From CNBC: 2024-08-21 13:22:39

Health-care marketplace Sesame introduces new $249/month clinical weight loss program offering compounded versions of Novo Nordisk’s Wegovy. Users can access branded drugs through the platform. Demand for weight loss and diabetes treatments is high- popular GLP-1 class medications expected to generate over $100 billion annually by 2030. Supply shortages challenge Novo Nordisk and Eli Lilly, leading to lawsuits over illicit versions, including overdosing concerns. Sesame partners with compounding pharmacy to ensure patient safety, offering consultations, lab work, and ongoing support. Nutritional, fitness, and mindfulness content library also available.



Read more at CNBC: Sesame to offer compounded Wegovy through weight loss program